Extracellular vesicles (EVs) are a promising carrier for targeted therapeutic delivery, but the development of EV technology has been hindered by poor scalability. We have developed a method to scale-up cellular production of nano-sized EVs by an order of magnitude using a sulfhydryl-blocking reagent. The Nanovesicles Induced by Sulfhydryl-blocking (NIbS) were loaded with chemotherapeutic doxorubicin. Tumor-bearing mice treated with drug-loaded NIbS showed improved survival outcomes and diminished tumor growth in comparison to those treated with free drug or the commercial liposomal formulation. Additionally, NIbS showed lower non-specific accumulation in the lungs and the liver. A versatile therapeutic carrier, NIbS overcome the traditional scalability problems associated with EV therapeutics.<br/>

Effective cancer therapy via therapeutic-loaded, cell-derived nanovesicles induced by sulfhydryl-blocking (NIbS)

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.